ARDELYX, INC.
For the period ended Mar 31, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 30, 2026
ARDX$3.01+2.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signature Summary of Abbreviated Terms
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Ardelyx, Inc. | ||
| Date: April 30, 2026 | By: | /s/ Joseph Reilly |
|---|---|---|
| Joseph ReillySenior Vice President and Chief Accounting Officer(Principal Accounting Officer) | ||
SUMMARY OF ABBREVIATED TERMS
Throughout this Quarterly Report on Form 10-Q, we have used terms which are defined below:
| 2025 Form 10-K | Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 19, 2026 | HCR | HealthCare Royalty Partners IV, L.P. |
|---|---|---|---|
| 340B Program | Public Health Service’s 340B Drug Pricing Program | HCR Agreement | Royalty and Sales Milestone Interest Acquisition Agreement |
| AAKP | American Association of Kidney Patients | HHS | Department of Health and Human Services |
| ACA | Affordable Care Act | HIPAA | Health Insurance Portability and Accountability Act of 1996, as amended, and regulations promulgated thereunder |
| AI Technologies | Artificial intelligence, machine learning and certain automated decision-making technologies | HRSA | Health Resources and Services Administration |
| AMP | average manufacturer price | IBS-C | irritable bowel syndrome with constipation |
| ANDA | abbreviated New Drug Application | IND | Investigational New Drug |
| API | active pharmaceutical ingredient | IRA | Inflation Reduction Act of 2022 |
| AstraZeneca | AstraZeneca AB | IRB | Institutional Review Board |
| ASU | Accounting Standards Update | IT | information technology |
| CCPA | California Consumer Privacy Act, as amended by the California Privacy Rights Act | Jefferies | Jefferies LLC |
| cGMP | current Good Manufacturing Practice | Knight | Knight Therapeutics, Inc. |
| CIC | chronic idiopathic constipation | Kyowa Kirin | Kyowa Kirin Co., Ltd. |
| CKD | chronic kidney disease | MDRP | Medicaid Drug Rebate Program |
| CME | Chicago Mercantile Exchange | MIPPA | Medicare Improvements for Patients andProviders Act |
| CMO | contract manufacturing organization | METiS | METiS Therapeutics, Inc. |
| CMS | Centers for Medicare & Medicaid Services | MHLW | Ministry of Health, Labour and Welfare |
| CRO | contract research organization | NCE | new chemical entity |
| Customers | collectively, major wholesalers, specialty pharmacies and GPOs (IBSRELA) and specialty wholesaler (XPHOZAH) | NDA | New Drug Application |
| DPF | EU-US Data Privacy Framework | NHE3 | sodium hydrogen exchange 3 |
| EEA | European Economic Area | NMPA | National Medical Products Administration |
| ESPP | Employee Stock Purchase Plan | NMQF | National Minority Quality Forum |
| ESRD | End-Stage Renal Disease | NOL | net operating loss |
| ESRD PPS | End-Stage Renal Disease Prospective Payment System | Non-FAMP | Non-Federal Average Manufacturer Price |
| EU Patent Package | European Patent Package | OLC | Oxylanthanum Carbonate |
| Exchange Act | the Securities Exchange Act of 1934, as amended | R&D | research and development |
| FASB | Financial Accounting Standards Board | REMS | Risk Evaluation and Mitigation Strategy |
| FDA | Food and Drug Administration | RSU | restricted stock units |
| FFDCA | Federal Food, Drug, and Cosmetic Act | SEC | Securities and Exchange Commission |
| Fosun Pharma | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | SLR | SLR Investment Corp. |
| FSS | Federal Supply Schedule | SOFR | Secured Overnight Financing Rate |
| FTC | Federal Trade Commission | TDAPA | Transitional Drug Add-on Payment Adjustment |
| GCP | Good Clinical Practice | UPC | European Unified Patent Court |
| GDPR | European Union General Data Protection Regulation | U.S. | United States |
| GLP | Good Laboratory Practice | USPTO | U.S. Patent and Trademark Office |
| GPO | group purchasing organization | VA | Department of Veterans Affairs |
| GTN | gross-to-net | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.